Psyence Biomedical Ltd. has announced a significant milestone in its ongoing Phase IIb clinical trial evaluating nature-derived psilocybin, in combination with psychotherapy, as a potential treatment for Adjustment Disorder in palliative care. Multiple patients have now been successfully dosed across two active clinical sites-the Empax Center in Perth and the Mind Medicine Australia Clinic in Melbourne. The company has also activated a third site, Paratus Clinical Research in Melbourne, to accelerate enrollment and data collection. The trial is designed to meet rigorous regulatory standards, with a larger sample size, randomized multi-site structure, and aims to generate high-quality data to support future approvals. Topline results from the study are anticipated by the end of 2026. No results have been presented yet.